TY - JOUR
T1 - Pseudoexfoliation in the Reykjavik Eye Study
T2 - Five-Year Incidence and Changes in Related Ophthalmologic Variables
AU - Arnarsson, Arsaell
AU - Damji, Karim F.
AU - Sasaki, Hiroshi
AU - Sverrisson, Thordur
AU - Jonasson, Fridbert
N1 - Funding Information:
This study was supported by a grant from St Joseph's Hospital Foundation, Reykjavik, Iceland; The University National Hospital and University of Iceland Research Grant, Reykjavik, Iceland; Helga Jonsdottir and Sigurlidi Kristjansson Memorial Research Fund, Reykjavik, Iceland; and the Prevention of Blindness Fund, Reykjavik, Iceland. The authors indicate no financial conflict of interest. Involved in design and conduct of study (A.A., K.F.D., H.S., T.S., F.J.); collection of data (A.A., K.F.D., H.S., T.S., F.J.); analysis, management, and interpretation of data (A.A., K.F.D., F.J.); writing of the article (A.A., K.F.D., H.S., T.S., F.J.); and review and preparation of manuscript (A.A., K.F.D., H.S., T.S., F.J.). This study was approved by the Ministry of Health, Ethics Committee/Review Board, Iceland, and by the Data Protection Authority, Iceland. The study was in accordance with the Declaration of Helsinki.
PY - 2009/8
Y1 - 2009/8
N2 - Purpose: To examine the 5-year incidence of pseudoexfoliation (PEX) and monitor changes in related ophthalmologic variables. Design: Population-based, prospective cohort study. Methods: A random sample from the Reykjavik Population Census for persons 50 years and older was used. At baseline 1,045 participants were examined for signs of PEX including peripheral band and/or central shield of exfoliative material on the anterior lens capsule. Five years later, 846 (88.2%) of survivors returned for a follow-up visit. Results: The 5-year incidence of PEX was 3.5% in right eyes only, and 5.2% in either eye. Age increased the risk of 5-year incidence by 5% when looking at 10-year age groups (P = .02); the incidence was higher in female subjects (P = .05) than in male. A total of 27% of clinically asymmetric cases converted to clinically bilateral disease over 5 years. Intraocular pressure increased in the group that developed PEX during the 5 years, but the size of the optic cup increased most in eyes that already had PEX at baseline. Conclusion: This incidence study from Iceland confirms findings from previous prevalence studies that PEX is increasingly common with older age in this population. Earliest changes related to PEX may be subtle and difficult to detect, which may lead to some misclassification. Further study is needed to identify clinical features that can reliably detect patients at risk for developing PEX.
AB - Purpose: To examine the 5-year incidence of pseudoexfoliation (PEX) and monitor changes in related ophthalmologic variables. Design: Population-based, prospective cohort study. Methods: A random sample from the Reykjavik Population Census for persons 50 years and older was used. At baseline 1,045 participants were examined for signs of PEX including peripheral band and/or central shield of exfoliative material on the anterior lens capsule. Five years later, 846 (88.2%) of survivors returned for a follow-up visit. Results: The 5-year incidence of PEX was 3.5% in right eyes only, and 5.2% in either eye. Age increased the risk of 5-year incidence by 5% when looking at 10-year age groups (P = .02); the incidence was higher in female subjects (P = .05) than in male. A total of 27% of clinically asymmetric cases converted to clinically bilateral disease over 5 years. Intraocular pressure increased in the group that developed PEX during the 5 years, but the size of the optic cup increased most in eyes that already had PEX at baseline. Conclusion: This incidence study from Iceland confirms findings from previous prevalence studies that PEX is increasingly common with older age in this population. Earliest changes related to PEX may be subtle and difficult to detect, which may lead to some misclassification. Further study is needed to identify clinical features that can reliably detect patients at risk for developing PEX.
UR - http://www.scopus.com/inward/record.url?scp=67650417880&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2009.03.021
DO - 10.1016/j.ajo.2009.03.021
M3 - Article
C2 - 19427619
AN - SCOPUS:67650417880
SN - 0002-9394
VL - 148
SP - 291
EP - 297
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
IS - 2
ER -